| Jun 4 |
Dow Surges 200 Points; Designer Brands Shares Plunge Following Q1 Earnings
|
| Jun 4 |
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
|
| Jun 4 |
Mid-Cap Firm Annexon's Nerve Disorder Candidate Shows Promise In Pivotal Late-Stage Study
|
| Jun 4 |
Biggest stock movers today: GME, HQY, and more
|
| Jun 4 |
Annexon spikes as lead asset hits main goal in late-stage study
|
| Jun 4 |
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
|
| Jun 4 |
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
| Jun 3 |
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
|
